Particularly, several clinical studies have reported the efficacy of ICIs or ICI-combined chemotherapy (chemo-ICI) for the treatment of patients with NSCLC who had high programmed death-ligand 1 (PD-L1) expression [5–15]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.